The Quantellect read.As of Nov 19, 2026, 6 active firms cover Amneal Pharmaceuticals, Inc. Class A Common Stock: 6 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $17.00 to $27.00, a moderate spread. The average target of $22.67 sits 4% above the current $21.90. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 5 to 6 over recent months. On the fundamentals, the Street sees revenue growth near 3% this year and 7% next, consensus EPS building from about $0.26 next quarter toward $1.23 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 active firms
Buy
Strong Buy00%
Buy6100%
Neutral00%
Sell00%
Strong Sell00%
Based on 6 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$22.67
+3.5% upside
Average target across 6 active firms as of Nov 19, 2026 vs $21.90 current
Highest Target$27.00
Average Target$22.67
Lowest Target$17.00
Detailed analyst forecasts for AMRX
Showing 1–5 of 5 named analysts shown · 6 active firms in the rating projection
As of Nov 19, 2026, 6 of 6 active firms rate AMRX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
AMRX EPS & revenue forecast
EPS · NEXT QUARTER
$0.26
Range $0.24 – $0.28 · 5 analysts · -4% YoY
Next period, 5 analysts expect Amneal Pharmaceuticals, Inc. Class A Common Stock to earn $0.26 a share (range $0.24 – $0.28), versus $0.27 a year earlier. Full-year consensus is $1.07, growing to $1.23 the year after.
REVENUE · NEXT QUARTER
$799.4M
Range $769.3M – $836.1M · 5 analysts · +3% YoY
Revenue is expected to reach $799.4M (range $769.3M – $836.1M), +3.0% year-over-year. Full-year consensus is $3.2B, rising to $3.5B next year.
Top analysts covering Amneal Pharmaceuticals, Inc. Class A Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on AMRX.
#1
David Amsellem
Piper Sandler · Rank #124
Buy
$17.00-22.4% to target
Overall win rate
50%
+ Follow
#2
Balaji Prasad
Barclays · Rank #226
Buy
$11.00-49.8% to target
Overall win rate
45%
+ Follow
#3
CS
Chris Schott
JP Morgan · Rank #287
Buy
$24.00+9.6% to target
Overall win rate
41%
+ Follow
#4
GS
Glen Santangelo
Barclays
Buy
$20.00-8.7% to target
Coverage
—
+ Follow
#5
Ashwani Verma
UBS
Buy
$25.00+14.2% to target
Coverage
—
+ Follow
AMRX stock forecast FAQ
What is AMRX's average 12-month price target?+
The 6 active firms with a live target average $22.67 for Amneal Pharmaceuticals, Inc. Class A Common Stock over the next 12 months, ranging from a $27.00 high to a $17.00 low, as of Nov 19, 2026.
Is AMRX stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 6 active firms as of Nov 19, 2026, 6 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for AMRX?+
The Street-high target is $27.00 (Oppenheimer), and the Street-low is $17.00 (Truist Securities). The average of all 6 active-firm targets is $22.67.
How many active Wall Street firms cover AMRX?+
6 active firms have a recognized rating on Amneal Pharmaceuticals, Inc. Class A Common Stock as of Nov 19, 2026, and 6 active firms carry a live 12-month price target.
Who is the most accurate analyst covering AMRX?+
Among analysts who currently cover AMRX, David Amsellem of Piper Sandler has the strongest overall Quantellect track record (Rank #124). Their current call is Buy with a $17.00 target.
What is Amneal Pharmaceuticals, Inc. Class A Common Stock's projected EPS for next quarter?+
The consensus estimate is $0.26 per share (range $0.24 – $0.28) across 5 analysts. Full-year EPS is projected at $1.07, rising to $1.23 the following year.
How much revenue is Amneal Pharmaceuticals, Inc. Class A Common Stock expected to report next quarter?+
Consensus revenue is $799.4M (range $769.3M – $836.1M). Full-year revenue is projected at $3.2B, growing to $3.5B next year.
Have analysts been upgrading or downgrading AMRX lately?+
As of Nov 19, 2026, 6 of 6 active firms rate AMRX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their AMRX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.